Also known as Invega
Paliperidone (trade name Invega), also known as 9-hydroxyrisperidone, is a dopamine antagonist of the atypical antipsychotic class of medications. It is developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone palmitate (trade name Invega Sustenna, named Xeplion in Europe) is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-monthly injection after an initial titration period. Paliperidone is used to treat mania and at lower doses as maintenance for bipolar disorder. It is also used for schizophrenia and schizoaffective disorder.Source: Wikipedia
Estimated Total Cost: $626.49 for an average of 28 days supply
Patients are most commonly prescribed paliperidone to treat schizophrenia, bipolar disorder, alcohol abuse, and psychotic disorder.
Patients taking paliperidone most commonly experience side effects like headache, vomiting, and increased heart rate.